pulmonary hypertensionin infants and children
DESCRIPTION
Dr. Maynard’s update on pulmonary hypertension in infants and children (presented on 6/22/11).TRANSCRIPT
![Page 1: Pulmonary Hypertensionin Infants and Children](https://reader034.vdocuments.net/reader034/viewer/2022042714/54c902654a7959fb4e8b4569/html5/thumbnails/1.jpg)
Pulmonary Hypertension
in Infants and Children
Roy Maynard, M.D.
June 22, 2011
![Page 2: Pulmonary Hypertensionin Infants and Children](https://reader034.vdocuments.net/reader034/viewer/2022042714/54c902654a7959fb4e8b4569/html5/thumbnails/2.jpg)
2 of 44
Objectives
• Understand the difference between neonatal
and pediatric pulmonary hypertension.
• Describe the best test to confirm pulmonary
hypertension.
• Identify the 3 metabolic pathways for current
pharmacologic approach to treating
pulmonary hypertension.
![Page 3: Pulmonary Hypertensionin Infants and Children](https://reader034.vdocuments.net/reader034/viewer/2022042714/54c902654a7959fb4e8b4569/html5/thumbnails/3.jpg)
3 of 44
Definition
• Increase in pulmonary artery (PA) pressure in the pulmonary vascular bed
• PA pressure >25 mmHg at rest or >30 mmHg with exercise
• Systolic PA pressure > half systolic systemic pressure
![Page 4: Pulmonary Hypertensionin Infants and Children](https://reader034.vdocuments.net/reader034/viewer/2022042714/54c902654a7959fb4e8b4569/html5/thumbnails/4.jpg)
4 of 44
Causes of Pulmonary Hypertension
• Neonatal
• Cardiac
• Acquired
• Idiopathic
• (New Classification Scheme Lists 10 Groups)
![Page 5: Pulmonary Hypertensionin Infants and Children](https://reader034.vdocuments.net/reader034/viewer/2022042714/54c902654a7959fb4e8b4569/html5/thumbnails/5.jpg)
5 of 44
Neonatal
• Persistent pulmonary hypertension of the newborn (persistent fetal circulation)
• Bronchopulmonary dysplasia
• Infection
• Structural disease
– Congenital diaphragmatic hernia
– Pulmonary hypoplasia
![Page 6: Pulmonary Hypertensionin Infants and Children](https://reader034.vdocuments.net/reader034/viewer/2022042714/54c902654a7959fb4e8b4569/html5/thumbnails/6.jpg)
6 of 44
Persistent Fetal Circulation
http://msrcol.org/nu/pphn.gif
![Page 7: Pulmonary Hypertensionin Infants and Children](https://reader034.vdocuments.net/reader034/viewer/2022042714/54c902654a7959fb4e8b4569/html5/thumbnails/7.jpg)
7 of 44
Conditions Predisposing to Neonatal Pulmonary Hypertension
• Respiratory Distress Syndrome
• Asphyxia
• Congenital diaphragmatic hernia
• Hypoglycemia/hypothermia
• Meconium aspiration syndrome
• Pulmonary hypoplasia
• Sepsis/pneumonia
• Pneumothorax
• Polycythemia
![Page 8: Pulmonary Hypertensionin Infants and Children](https://reader034.vdocuments.net/reader034/viewer/2022042714/54c902654a7959fb4e8b4569/html5/thumbnails/8.jpg)
8 of 44
Treatment of Neonatal Pulmonary Hypertension
• Persistent Pulmonary Hypertension of the Newborn
– Oxygen
– Decrease stress
– IV dextrose/antibiotics
– Intubation/mechanical ventilation
– High frequency ventilation
– Surfactant therapy
– Neuromuscular paralysis
– Pressors
– Nitric oxide
– Sildenafil
– Steroids?
![Page 9: Pulmonary Hypertensionin Infants and Children](https://reader034.vdocuments.net/reader034/viewer/2022042714/54c902654a7959fb4e8b4569/html5/thumbnails/9.jpg)
9 of 44
Bronchopulmonary Dysplasia
• Elevated pulmonary pressures very common in patients with moderately severe to severe disease
• Aim to keep oxygen sats >95
• Exacerbated by infection
• Pulmonary hypertensive crisis uncommon
• May benefit by tracheostomy and long-term mechanical ventilation
• Generally improves with time and normal lung remodeling and growth
• Death from progressive pulmonary hypertension is uncommon
![Page 10: Pulmonary Hypertensionin Infants and Children](https://reader034.vdocuments.net/reader034/viewer/2022042714/54c902654a7959fb4e8b4569/html5/thumbnails/10.jpg)
10 of 44
Pulmonary Hypoplasia/CDH
Normal lung
Hypoplastic lung Pulmonary arterioles
![Page 11: Pulmonary Hypertensionin Infants and Children](https://reader034.vdocuments.net/reader034/viewer/2022042714/54c902654a7959fb4e8b4569/html5/thumbnails/11.jpg)
11 of 44
Pathophysiology of Pulmonary Hypertension
• Small vascular bed
• Reversible vasoconstricted vascular bed
• Structural alterations to the vascular bed
– Primarily arterioles
– Small to medium-sized pulmonary arteries
– May affect all three components of the artery:
intima (endothelial cells), media (smooth muscle
cells), adventitia (collagen, fibroblasts)
![Page 12: Pulmonary Hypertensionin Infants and Children](https://reader034.vdocuments.net/reader034/viewer/2022042714/54c902654a7959fb4e8b4569/html5/thumbnails/12.jpg)
12 of 44
Pulmonary Hypertension
Beyond the Newborn
Intensive Care Unit
![Page 13: Pulmonary Hypertensionin Infants and Children](https://reader034.vdocuments.net/reader034/viewer/2022042714/54c902654a7959fb4e8b4569/html5/thumbnails/13.jpg)
13 of 44
Epidemiology
• Idiopathic in 35% of pediatric patients
• Associated with congenital heart disease in
52% of pediatric patients
• Slightly more common in girls
• Median age of diagnosis age 3
• Disease tends to progress more rapidly in
children relative to adults
![Page 14: Pulmonary Hypertensionin Infants and Children](https://reader034.vdocuments.net/reader034/viewer/2022042714/54c902654a7959fb4e8b4569/html5/thumbnails/14.jpg)
14 of 44
Cardiac Structural Heart Disease
• Left-to-right shunt VSD, AV canal, PDA, AP
window
• Transposition of the great arteries
• Obstructive lesions TAPVC, MS, HLHS,
Cardiomyopathy
• Eisenmenger syndrome: elevated pulmonary
vascular resistance and pulmonary hypertension
induced reversal of a previous left-to-right shunt
![Page 15: Pulmonary Hypertensionin Infants and Children](https://reader034.vdocuments.net/reader034/viewer/2022042714/54c902654a7959fb4e8b4569/html5/thumbnails/15.jpg)
15 of 44
Acquired
• Chronic hypoxia, cystic fibrosis, high altitude
• Scoliosis with severe restrictive disease
• Airway obstruction
• Vasculitic connective tissue disease,
interstitial lung disease, sickle cell
![Page 16: Pulmonary Hypertensionin Infants and Children](https://reader034.vdocuments.net/reader034/viewer/2022042714/54c902654a7959fb4e8b4569/html5/thumbnails/16.jpg)
16 of 44
Idiopathic
• Sporadic 20% genetic in origin
• 6–10% of idiopathic cases are familial with
autosomal dominant pattern
• Females > males (1.7:1)
• Bone morphogenetic protein gene (BMP II)
responsible in 50% of familial and 10% of
sporadic
![Page 17: Pulmonary Hypertensionin Infants and Children](https://reader034.vdocuments.net/reader034/viewer/2022042714/54c902654a7959fb4e8b4569/html5/thumbnails/17.jpg)
17 of 44
Bone Morphogenetic Protein Receptor 2
• BMPR2
• A transforming growth factor
• A decrease in BMPR2 expression
(downregulation) leads to abnormal
proliferative responses in pulmonary
vascular cells
![Page 18: Pulmonary Hypertensionin Infants and Children](https://reader034.vdocuments.net/reader034/viewer/2022042714/54c902654a7959fb4e8b4569/html5/thumbnails/18.jpg)
18 of 44
Bone Morphogenetic Protein Receptor 2
http://img.medscape.com/fullsize/migrated/527/555/pharm527555.fig1.gif
![Page 19: Pulmonary Hypertensionin Infants and Children](https://reader034.vdocuments.net/reader034/viewer/2022042714/54c902654a7959fb4e8b4569/html5/thumbnails/19.jpg)
19 of 44
Other Diagnoses
• Collagen vascular disease
• Sickle cell disease
• Down’s syndrome
• Eisenmenger syndrome
![Page 20: Pulmonary Hypertensionin Infants and Children](https://reader034.vdocuments.net/reader034/viewer/2022042714/54c902654a7959fb4e8b4569/html5/thumbnails/20.jpg)
20 of 44
Clinical
• History (SILENT DISEASE)
– Heart disease
– Shortness of breath
– Syncope
– Poor endurance/fatigue
– Cyanotic spells
– Symptoms not present till pressures > 60
– Poor appetite/failure to thrive
– Irritability
![Page 21: Pulmonary Hypertensionin Infants and Children](https://reader034.vdocuments.net/reader034/viewer/2022042714/54c902654a7959fb4e8b4569/html5/thumbnails/21.jpg)
21 of 44
Clinical
• Physical Exam
– Right ventricular heave
– Increased 2nd heart sound
– Diastolic heart murmur
– Tachycardia
– Tachypnea
– Diaphoresis
– Peripheral edema/acrocyanosis
![Page 22: Pulmonary Hypertensionin Infants and Children](https://reader034.vdocuments.net/reader034/viewer/2022042714/54c902654a7959fb4e8b4569/html5/thumbnails/22.jpg)
22 of 44
Clinical
• Laboratory
– Pulse oximetry usually normal
– Exercise testing
– ECG - RVH
– Echocardiogram: dilated right heart
chamber, right ventricular hypertrophy,
tricuspid regurgitation, paradoxical
motion of cardiac septum
![Page 23: Pulmonary Hypertensionin Infants and Children](https://reader034.vdocuments.net/reader034/viewer/2022042714/54c902654a7959fb4e8b4569/html5/thumbnails/23.jpg)
23 of 44
Right-Sided Heart Failure
http://healthguide.howstuffworks.com/cor-pulmonale-picture.htm
![Page 24: Pulmonary Hypertensionin Infants and Children](https://reader034.vdocuments.net/reader034/viewer/2022042714/54c902654a7959fb4e8b4569/html5/thumbnails/24.jpg)
24 of 44
Clinical
• Laboratory
– CXR - enlarged central pulmonary arteries,
pruning of peripheral pulmonary arteries
– CT scan of chest – R/O interstitial lung
disease, hemangiomatosis, thromboembolic
defects
– Pulmonary function testing
– Lung biopsy – veno-occlusive disease
![Page 25: Pulmonary Hypertensionin Infants and Children](https://reader034.vdocuments.net/reader034/viewer/2022042714/54c902654a7959fb4e8b4569/html5/thumbnails/25.jpg)
25 of 44
Pulmonary Hypertension
http://ph-central.com/2011/03/the-secondary-pulmonary-hypertension-causes-prognosis-treatment.html
![Page 27: Pulmonary Hypertensionin Infants and Children](https://reader034.vdocuments.net/reader034/viewer/2022042714/54c902654a7959fb4e8b4569/html5/thumbnails/27.jpg)
27 of 44
Histopathology
http://www.pvrireview.org/article.asp?issn=0974-
6013%3Byear=2009%3Bvolume=1%3Bissue=1%3Bspage=34%3Bepage=38%3Baulast=Aiello
![Page 28: Pulmonary Hypertensionin Infants and Children](https://reader034.vdocuments.net/reader034/viewer/2022042714/54c902654a7959fb4e8b4569/html5/thumbnails/28.jpg)
28 of 44
Pathophysiology of Pulmonary Hypertension
• Small vascular bed
• Reversible vasoconstricted vascular bed
• Structural alterations to the vascular bed
– Primarily arterioles
– Small to medium-sized pulmonary arteries
– May affect all three components of the artery; intima (endothelial cells), media (smooth muscle cells), adventitia (collagen, fibroblasts)
![Page 29: Pulmonary Hypertensionin Infants and Children](https://reader034.vdocuments.net/reader034/viewer/2022042714/54c902654a7959fb4e8b4569/html5/thumbnails/29.jpg)
29 of 44
Pulmonary Hypertension
http://www.riversideonline.com/source/images/image_popup/r7_pulmonaryhypertens.jpg
![Page 30: Pulmonary Hypertensionin Infants and Children](https://reader034.vdocuments.net/reader034/viewer/2022042714/54c902654a7959fb4e8b4569/html5/thumbnails/30.jpg)
30 of 44
Clinical
• Blood work
– Gene testing (BMPR2)
– Thyroid function
– Thrombophilia screen
– Antiphospholipid antibody
![Page 31: Pulmonary Hypertensionin Infants and Children](https://reader034.vdocuments.net/reader034/viewer/2022042714/54c902654a7959fb4e8b4569/html5/thumbnails/31.jpg)
31 of 44
Clinical
• Gold Standard Cardiac Catherization
– Direct measure of PA pressure
– Calculate pulmonary vascular resistance
– Cardiac output
– Pulmonary vasoreactivity – prognosticate
• Oxygen
• Sildenafil
• Nitric oxide
• Prostacyclin
![Page 32: Pulmonary Hypertensionin Infants and Children](https://reader034.vdocuments.net/reader034/viewer/2022042714/54c902654a7959fb4e8b4569/html5/thumbnails/32.jpg)
32 of 44
WHO Functional Classification of Pulmonary Hypertension
• Class I: Ordinary physical activity does not cause undue dyspnea, fatigue, chest pain or near syncope
• Class II: Comfortable at rest, ordinary physical activity causes undue dyspnea, fatigue, chest pain or near syncope
• Class III: Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes undue dyspnea, fatigue, chest pain or near syncope
• Class IV: Unable to perform any physical activity without symptoms. These patients manifest signs of right heart failure. Dyspnea and/or fatigue may be present at rest. Discomfort is increased with any physical activity.
![Page 33: Pulmonary Hypertensionin Infants and Children](https://reader034.vdocuments.net/reader034/viewer/2022042714/54c902654a7959fb4e8b4569/html5/thumbnails/33.jpg)
33 of 44
Treatment of Pediatric Pulmonary Hypertension
Prostacyclin Pathway
Nitric Oxide Pathway Endothelin Pathway
Obliterated arteriole
proendothelin
Arginine -> Citrulline
Arachadonic acid -> prostaglandin I2
Endothelin-1
Nitric oxide
Phosphodiester
ase type - 5
cGMP
Vasodilitation
Antiproliferation
sildenafil
Endothelial cells
Smooth muscle cells
prostacyclin
cAMP
Vasodilitation
Antiproliferation
Block endothelial receptors
With bosentan ; results in vasodilitation
And antiproliferation
![Page 34: Pulmonary Hypertensionin Infants and Children](https://reader034.vdocuments.net/reader034/viewer/2022042714/54c902654a7959fb4e8b4569/html5/thumbnails/34.jpg)
34 of 44
Pharmacologic Treatment
• Calcium Channel Blockers
– Nifidipine
– Small percentage are acute responders
– 50% acute responders lose beneficial effect
within one year
![Page 35: Pulmonary Hypertensionin Infants and Children](https://reader034.vdocuments.net/reader034/viewer/2022042714/54c902654a7959fb4e8b4569/html5/thumbnails/35.jpg)
35 of 44
Pharmacologic Treatment
• Endothelin 1-Receptor Antagonists
– Two receptors A and B
• Receptor A vasoconstriction
• Receptor B vasodilitation and anti-mitogenic
– Potent vasoconstrictors and mitogens
• Bosentan (A&B)
• Sitaxetan (A)
• Ambrisentan (A)
![Page 36: Pulmonary Hypertensionin Infants and Children](https://reader034.vdocuments.net/reader034/viewer/2022042714/54c902654a7959fb4e8b4569/html5/thumbnails/36.jpg)
36 of 44
Pharmacologic Treatment
• Phosphodiesterase-5 Inhibitors
– Vasodilitation and antiproliferation
– Work through nitric oxide/cyclic
guanosine monophosphate pathway
– Sildenafil
– Tadalafil
![Page 37: Pulmonary Hypertensionin Infants and Children](https://reader034.vdocuments.net/reader034/viewer/2022042714/54c902654a7959fb4e8b4569/html5/thumbnails/37.jpg)
37 of 44
Pharmacologic Treatment
• Prostanoids
– Epoprostenol IV (most experience)
– Treprostinil IV or SQ (painful SQ)
– Iloprost nebulized
– Beraprost oral (less efficacious)
• Side Effects
– Flushing, jaw pain, headaches, rashes,
thrombocytopenia
![Page 38: Pulmonary Hypertensionin Infants and Children](https://reader034.vdocuments.net/reader034/viewer/2022042714/54c902654a7959fb4e8b4569/html5/thumbnails/38.jpg)
38 of 44
Pharmacologic Treatment
• Combination Therapy
• Rho-kinase inhibitors (promote vasodilitation)
• Vasoactive Intestinal Polypeptide (VIP)
• Anticoagulation (reduced cardiac output,
polycythemia)
• Glucocorticoids for co-existing diseases like
collagen vascular disease
![Page 39: Pulmonary Hypertensionin Infants and Children](https://reader034.vdocuments.net/reader034/viewer/2022042714/54c902654a7959fb4e8b4569/html5/thumbnails/39.jpg)
39 of 44
Non-Pharmacologic Therapies
• Atrial septostomy – Create pop-off between right and left atrium
– Improves syncopal episodes
– Improves right heart failure
– Improves survival
• Lung or lung/heart transplant – 77% survival one year
– 62% survival two years
– 55% survival five years
– 10% survival ten years
![Page 40: Pulmonary Hypertensionin Infants and Children](https://reader034.vdocuments.net/reader034/viewer/2022042714/54c902654a7959fb4e8b4569/html5/thumbnails/40.jpg)
40 of 44
Clinical Endpoints
• 6-minute walk test
• Time to clinical worsening
• Quality of life
• Echocardiogram
• Heart catherization
![Page 41: Pulmonary Hypertensionin Infants and Children](https://reader034.vdocuments.net/reader034/viewer/2022042714/54c902654a7959fb4e8b4569/html5/thumbnails/41.jpg)
41 of 44
Prognosis
• Survival better with secondary pulmonary
hypertension than with idiopathic pulmonary
hypertension
• UK Pulmonary Hypertension Service for
Children
– 85.6% one-year survival
– 79.9% three-year survival
– 71.9% five-year survival
![Page 42: Pulmonary Hypertensionin Infants and Children](https://reader034.vdocuments.net/reader034/viewer/2022042714/54c902654a7959fb4e8b4569/html5/thumbnails/42.jpg)
42 of 44
Conclusion
• Improved understanding of genetic aspects of familial pulmonary hypertension may lead to new therapies
• Much better delineation of pathobiology causing pulmonary hypertension now
• New pharmacological approaches to treating pulmonary hypertension have prolonged and improved quality of life
• None of these interventions have cured pulmonary hypertension
![Page 43: Pulmonary Hypertensionin Infants and Children](https://reader034.vdocuments.net/reader034/viewer/2022042714/54c902654a7959fb4e8b4569/html5/thumbnails/43.jpg)
43 of 44
Conclusion
• Limited pharmacologic data for pulmonary hypertension treatment in children
• Most treatment schemes extrapolated from adults to children though pulmonary hypertension may be more prevalent in children
• Difficult to measure clinical endpoints in children
• Placebo-controlled studies are difficult to conduct and may be deemed ethically unacceptable
![Page 44: Pulmonary Hypertensionin Infants and Children](https://reader034.vdocuments.net/reader034/viewer/2022042714/54c902654a7959fb4e8b4569/html5/thumbnails/44.jpg)
44 of 44
Q&A
Thank you for attending!